Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes

Area of Science:

• Immunology
• Endocrinology
• Cell Biology

Background:

• Type 1 diabetes (T1D) involves autoimmune destruction of pancreatic beta cells.
• Regulatory T cells (Tregs) are vital for immune tolerance but show impaired function in T1D.
• Genetic, epigenetic, and cytokine signaling defects compromise Treg function in T1D pathogenesis.

Purpose of the Study:

• To review Treg biology, focusing on their compromised role in T1D.
• To explore the evolution of Treg-based immunotherapies, including genetically engineered Tregs (EngTregs).
• To synthesize current knowledge and outline future directions for Treg therapy in T1D.

Main Methods:

• Review of Treg biology, including development, phenotype, and function.
• Analysis of Treg characteristics within the pancreatic microenvironment.
• Exploration of advancements in EngTreg development, genome editing, and delivery technologies.

Main Results:

• Pancreatic Tregs exhibit unique chemokine receptor expression, migratory capacity, and metabolic adaptations.
• Genetically engineered Tregs (EngTregs) demonstrate potential for stable FoxP3 expression and antigen-specific targeting (TCRs/CARs).
• Preclinical studies show promise, but clinical translation faces significant challenges.

Conclusions:

• Understanding Treg biology is key to addressing their compromised role in T1D.
• Next-generation Treg therapies, particularly EngTregs, offer a promising avenue for achieving durable immune tolerance in T1D.
• Further advancements in technology and combination strategies are needed for successful clinical translation.